Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

ITCI

Get informed when a big investor buys or sells

+ Follow
Market Cap$14.05B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Intra-Cellular Therapies IncIntra-Cellular Therapies Inc-182.1--7%22-
$69.66

Current Fair Value

47.2% downside

Overvalued by 47.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$14.05 Billion
Enterprise Value$13.76 Billion
Dividend Yield$- (-)
Earnings per Share$-0.72
Beta0.46
Outstanding Shares103,131,017

Return

Return on Equity-6.50%ROE
Return on Assets-5.46%
Return on Invested Capital-10.05%

Valuation & Multiples

P/E Ratio-182.12P/E Ratio
PEG445.08PEG
Price to Sales21.98Price to Sales
Price to Book Ratio11.99Price to Book Ratio
Enterprise Value to Revenue20.21
Enterprise Value to EBIT-117.86
Enterprise Value to Net Income-185
Total Debt to Enterprise0
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Insider Trades

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

ESG Score

No data

About Intra-Cellular Therapies Inc

CEO: Sharon Mates

Relevant Senate Committees

Joint Committee on Taxation

This committee's role in scoring and influencing tax legislation directly impacts corporate tax structures and capital investment credits, which are critical financial factors for a manufacturing company like ITCI. Members would have direct insight into impending tax changes affecting corporate profitability.

Finance

This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy and, crucially, Medicare pricing and reimbursement rates directly and significantly impact ITCI's profitability and revenue streams for its products.

Appropriations

This committee allocates federal discretionary spending. Its decisions directly determine funding for health agencies (like NIH, which supports research relevant to ITCI) and procurement budgets for government entities that purchase pharmaceuticals (like the VA), directly impacting ITCI's potential R&D funding and sales opportunities.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which is the primary body responsible for drug approval, manufacturing standards, and marketing. Its oversight and legislative actions directly impact ITCI's product development, approval timelines, and market access.

Judiciary

This committee oversees intellectual property laws (patents are critical for pharmaceutical companies) and antitrust enforcement (relevant for mergers and market practices). Decisions here directly affect ITCI's core assets and competitive landscape.